{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:33:11Z","timestamp":1790346791993,"version":"4.1.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.4103\/idoj.idoj_355_22","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T09:37:54Z","timestamp":1682588274000},"page":"330","source":"Crossref","is-referenced-by-count":8,"title":["Nail Society of India (NSI) recommendations for pharmacologic therapy of onychomycosis"],"prefix":"10.4103","volume":"14","author":[{"given":"Chander","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushbu","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Relhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Tahiliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MManjunath","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Jakhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.375166-1","first-page":"92\u20137","article-title":"The non-dermatophyte molds: Emerging as leading cause of onychomycosis in south-east Rajasthan","author":"Raghavendra","year":"2015","journal-title":"Indian Dermatol Online J","ISSN":"https:\/\/id.crossref.org\/issn\/2229-5178","issn-type":"print"},{"key":"key-10.4103\/2229-5178.375166-2","first-page":"265\u201372","article-title":"A systematic review and meta-analysis on the epidemiology, casual agents and demographic characteristics of onychomycosis in Iran","author":"Rafat","year":"2019","journal-title":"J Mycol Medicale"},{"key":"key-10.4103\/2229-5178.375166-3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bjd.13358","article-title":"British Association of Dermatologists' guidelines for the management of onychomycosis 2014","author":"Ameen","year":"2014","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-4","unstructured":"OCEBM Levels of Evidence Working Group. \u201cThe Oxford 2011 Levels of Evidence\u201d. Oxford Centre for Evidence-Based Medicine. Available from http:\/\/www.cebm.net\/index.aspx?o=5653. [Last accessed on 2022 Jun 08]."},{"key":"key-10.4103\/2229-5178.375166-5","first-page":"939\u201344","article-title":"Onychomycosis: Diagnosis and definition of cure","author":"Scher","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4103\/0378-6323.86475","article-title":"Onychomycosis: Diagnosis and management","author":"Singal","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.375166-7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000469666","article-title":"Patient-reported outcomes in onychomycosis: A review of psychometrically evaluated instruments in assessing treatment effectiveness","author":"Wang","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"key-10.4103\/2229-5178.375166-8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: Treatment and prevention of recurrence","author":"Lipner","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-9","first-page":"1118\u201329","article-title":"Global perspectives for the management of onychomycosis","author":"Gupta","year":"2019","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-10","unstructured":"Gupta AK. Systemic Antifungal agents. In: Wolverton SE, Wu JJ, editors. Comprehensive Dermatologic Drug Therapy. 3rd ed. St. Louis, MO: Elsevier Health Sciences; 2019. p. 105."},{"key":"key-10.4103\/2229-5178.375166-11","first-page":"2\u20137","article-title":"Terbinafine: Mode of action and properties of the squalene epoxidase inhibition","author":"Ryder","year":"1992","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2011.02.038","article-title":"Systematic review of non-dermatophyte mold onychomycosis: Diagnosis, clinical types, epidemiology, and treatment","author":"Gupta","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2133.1997.6661651.x","article-title":"Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy.The Lagos V Study Group","author":"Tausch","year":"1997","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-14","first-page":"36","article-title":"A randomized treatment duration-finding study of terbinafine in onychomycosis","author":"Van","year":"1992","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-15","unstructured":"Consumer information. PrLAMISIL* (terbinafine hydrochloride) 250 mg tablets. Available from: https:\/\/www.novartis.ca\/sites\/www.novartis.ca\/files\/lamisil_patient_e_1.pdf. [Last accessed on 2022 Dec 27]."},{"key":"key-10.4103\/2229-5178.375166-16","first-page":"256\u201362","article-title":"The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis","author":"Gupta","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.375166-17","first-page":"259\u201362","article-title":"Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: A new approach","author":"Alpsoy","year":"1996","journal-title":"J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-18","first-page":"1253","article-title":"Intermittent terbinafine for toenail onychomycosis: Is it effective.Results of a randomized pilot trial?","author":"Warshaw","year":"2001","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.375166-19","first-page":"363","article-title":"Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial","author":"Yadav","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.375166-20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1468-3083.2012.04584.x","article-title":"Terbinafine in the treatment of dermatophyte toenail onychomycosis: A meta-analysis of efficacy for continuous and intermittent regimens","author":"Gupta","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.375166-21","doi-asserted-by":"crossref","unstructured":"Gupta AK. Systemic Antifungal agents. In: Wolverton SE, Wu JJ. Comprehensive Dermatologic Drug Therapy. 3rd ed. St. Louis, MO: Elsevier Health Sciences; 2019. p. 98-119.","DOI":"10.1016\/B978-1-4377-2003-7.00009-1"},{"key":"key-10.4103\/2229-5178.375166-22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/09546634.2019.1708242","article-title":"Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration","author":"Wang","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/2229-5178.375166-23","doi-asserted-by":"crossref","unstructured":"O'Sullivan DP, Needham CA, Bangs A, atkin K, Kendall FD. Postmarketing surveillance of oral terbinafine in the U.K.: Report of a large cohort study. Br J Clin Pharmacol 1996;42:559\u201365.","DOI":"10.1111\/j.1365-2125.1996.tb00049.x"},{"key":"key-10.4103\/2229-5178.375166-24","first-page":"e13111","article-title":"Terbinafine: Safety profile and monitoring in treatment of dermatophyte infections","author":"Sun","year":"2019","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.375166-25","first-page":"585\u2013620","article-title":"Itraconazole.A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections","author":"Haria","year":"1996","journal-title":"Drugs"},{"key":"key-10.4103\/2229-5178.375166-26","first-page":"491\u20137","article-title":"Treatment of nondermatophyte mold and Candida onychomycosis","author":"Tosti","year":"2003","journal-title":"Dermatol Clin"},{"key":"key-10.4103\/2229-5178.375166-27","first-page":"179\u201385","article-title":"In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species","author":"Gupta","year":"2005","journal-title":"Med Mycol"},{"key":"key-10.4103\/2229-5178.375166-28","first-page":"537\u201344","article-title":"Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis","author":"Gupta","year":"2004","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-29","first-page":"731\u20135","article-title":"Post-treatment itraconazole levels in the nail.New implications for treatment in onychomycosis","author":"Willemsen","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-30","first-page":"469\u201379","article-title":"The use of oral antifungal agents to treat onychomycosis","author":"Gupta","year":"2003","journal-title":"Dermatol Clin"},{"key":"key-10.4103\/2229-5178.375166-31","first-page":"6\u201310","article-title":"Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses","author":"Gupta","year":"2001","journal-title":"Eur J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-32","first-page":"758\u201363","article-title":"Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis","author":"Maddin","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"key-10.4103\/2229-5178.375166-33","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2229-5178.375166-34","first-page":"182\u201392","article-title":"The life-threatening complications of dermatologic therapies","author":"Orion","year":"2005","journal-title":"Clin Dermatol"},{"key":"key-10.4103\/2229-5178.375166-35","first-page":"CD010031","article-title":"Oral antifungal medication for toenail onychomycosis","author":"Kreijkamp-Kaspers","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/2229-5178.375166-36","doi-asserted-by":"crossref","unstructured":"Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis Ann Pharmacother 2009;43:1684\u201391.","DOI":"10.1345\/aph.1M165"},{"key":"key-10.4103\/2229-5178.375166-37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/09546634.2012.703308","article-title":"Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment","author":"Gupta","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/2229-5178.375166-38","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1517\/17425240802497218","article-title":"Enhancing the nail permeability of topically applied drugs","author":"Murdan","year":"2008","journal-title":"Exp Opin Drug Deliv"},{"key":"key-10.4103\/2229-5178.375166-39","first-page":"10\u20135","article-title":"Onychomycosis: Review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence","author":"Gupta","year":"2004","journal-title":"Cutis"},{"key":"key-10.4103\/2229-5178.375166-40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5114\/pdia.2014.40968","article-title":"Amorolfine vs.ciclopirox-lacquers for the treatment of onychomycosis","author":"Tabara","year":"2015","journal-title":"Postepy Dermatol Alergol"},{"key":"key-10.4103\/2229-5178.375166-41","first-page":"875\u20139","article-title":"Today's treatment options for onychomycosis","author":"Lorizzo","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"key-10.4103\/2229-5178.375166-42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1439-0507.2012.02199.x","article-title":"An update on treatment of onychomycosis","author":"Grover","year":"2012","journal-title":"Mycoses"},{"key":"key-10.4103\/2229-5178.375166-43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/2211738507666190228104031","article-title":"Novel Drug Delivery Strategies for the Treatment of Onychomycosis","author":"Dhamoon","year":"2019","journal-title":"Pharm Nanotechnol"},{"key":"key-10.4103\/2229-5178.375166-44","first-page":"350","article-title":"Fungicidal drugs induce a common oxidative-damage cellular death pathway","author":"Wolverton,","year":"2013","journal-title":"Cell Rep"},{"key":"key-10.4103\/2229-5178.375166-45","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1067\/mjd.2000.109072","article-title":"Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis","author":"Bohn","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-46","unstructured":"Aventis Pharma. Penlac (Ciclopirox Topical Solution, 8% w\/w) Nail Lacquer. Available from https:\/\/pdf.hres.ca\/dpd_pm\/00015736.PDF. [Last accessed on 2022 Jun 08]."},{"key":"key-10.4103\/2229-5178.375166-47","unstructured":"Galderma (U.K) Ltd. Curanail 5% w\/v Medicated Nail Lacquer. Available from https:\/\/www.medicines.org.uk\/emc\/prod uct\/9436\/smpc. [Last accessed on 2022 Jun 08]."},{"key":"key-10.4103\/2229-5178.375166-48","first-page":"17","article-title":"A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers","author":"Sidou","year":"2004","journal-title":"Int J Tissue React"},{"key":"key-10.4103\/2229-5178.375166-49","first-page":"910\u20135","article-title":"Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years","author":"Sigurgeirsson","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.375166-50","first-page":"21\u20134","article-title":"Topical treatment of onychomycosis with amorolfine 5% nail lacquer: Comparative efficacy and tolerability of once and twice weekly use","author":"Reinel","year":"1992","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.375166-51","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/j.1468-3083.2012.04529.x","article-title":"Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs.a standard amorolfine lacquer in healthy subjects","author":"Monti","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.375166-52","unstructured":"Brown M, Turner R, Nakamura N. Nail permeation and depth profiling of luliconazole, a novel imidazole antifungal agent, for the topical treatment of onychomycosis. Poster presented at the 53rd Inter- science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 10\u201313, Denver, CO, USA, 2013."},{"key":"key-10.4103\/2229-5178.375166-53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/1346-8138.13816","article-title":"Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study","author":"Watanabe","year":"2017","journal-title":"J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-54","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/jdv.16394","article-title":"Onychomycosis: A review","author":"Gupta","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.375166-55","first-page":"600\u20138","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies","author":"Elewski","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-56","first-page":"5","article-title":"Long-term efficacy and safety of once-daily efinaconazole 10% topical solution (Jublia) for dermatophyte toenail onychomycosis: An interim analysis","author":"Gupta","year":"2021","journal-title":"Skin Therapy Lett"},{"key":"key-10.4103\/2229-5178.375166-57","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","author":"Rock","year":"2007","journal-title":"Science"},{"key":"key-10.4103\/2229-5178.375166-58","unstructured":"Kerydin (tavaborole) topical solution, 5% [package insert]. Melville, NY: Fougera Pharmaceuticals. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid51ae61072-bca0-43f0-a741-07bda2d50c87. [Last accessed on 2022 Jun 08]."},{"key":"key-10.4103\/2229-5178.375166-59","first-page":"CD012093","article-title":"Topical and device-based treatments for fungal infections of the toenails","author":"Foley","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/2229-5178.375166-60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/myc.13392","article-title":"A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis","author":"Blume-Peytavi","year":"2022","journal-title":"Mycoses"},{"key":"key-10.4103\/2229-5178.375166-61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaad.2020.06.055","article-title":"Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study","author":"Gupta","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000433473","article-title":"Network meta-analysis of onychomycosis treatments","author":"Gupta","year":"2015","journal-title":"Skin Appendage Disord"},{"key":"key-10.4103\/2229-5178.375166-63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-3083.2004.00988.x","article-title":"Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy","author":"Baran","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.375166-64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2133.2007.07974.x","article-title":"A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement","author":"Baran","year":"2007","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.375166-65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/09546630500420183","article-title":"Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis","author":"Avner","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/2229-5178.375166-66","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1067\/mjd.2001.110644","article-title":"Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis","author":"Gupta","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000018363","article-title":"The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse-dosing regimen","author":"Pi\u00e9rard","year":"2000","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.375166-68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/mmy.38.5.391.392","article-title":"The boosted antifungal topical treatment (BATT) for onychomycosis","author":"Pierard","year":"2000","journal-title":"Med Mycol"},{"key":"key-10.4103\/2229-5178.375166-69","unstructured":"Mahajan K, Sharma S, Sardana K, Gupta A. Superficial fungal infections. In: Sardana K, Mahajan K, Mrig PA, editors. Fungal Infections Diagnosis and Treatment. 1st ed. CBS Publishers; 2017. p. 103-5."},{"key":"key-10.4103\/2229-5178.375166-70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13047-019-0332-3","article-title":"The use of urea for the treatment of onychomycosis: A systematic review","author":"Dars","year":"2019","journal-title":"J Foot Ankle Res"},{"key":"key-10.4103\/2229-5178.375166-71","first-page":"411\u20134","article-title":"Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents","author":"Piraccini","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-72","first-page":"1241\u20136","article-title":"The role of biofilms in onychomycosis","author":"Gupta","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.375166-73","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.foot.2008.03.005","article-title":"Treatment of tinea pedis with socks containing copper-oxide impregnated fibers","author":"Zatcoff","year":"2008","journal-title":"Foot (Edinb)"},{"key":"key-10.4103\/2229-5178.375166-74","doi-asserted-by":"crossref","unstructured":"Shemer A, Gupta AK, Kamshov A, Babaev M, Farhi R, Daniel CR 3rd, et al. Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatol Ther 2017;30. doi: 10.1111\/dth.12545.","DOI":"10.1111\/dth.12545"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:48:10Z","timestamp":1787165290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_355_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"alternative-id":["375166"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_355_22","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}